CRISPR Therapeutics AG (CRSP) Share-based Compensation (2015 - 2026)

CRISPR Therapeutics AG has disclosed Share-based Compensation across 12 years of filings, most recently posting $16.3 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.3 million, down 19.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.6 million (down 21.47% YoY), and the FY2025 annual result was $72.5 million, down 16.25% from the prior year.
• Share-based Compensation came in at $16.3 million for Q1 2026 at CRISPR Therapeutics AG, down from $18.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $25.7 million in Q1 2022 to a low of $16.3 million in Q1 2026.
• The 5-year median for Share-based Compensation is $20.9 million (2023), against an average of $20.8 million.
• Across the five-year window, Share-based Compensation climbed 19.15% in 2024 and fell 25.62% in 2025, its largest moves.
• CRISPR Therapeutics AG's Share-based Compensation stood at $22.8 million in 2022, then declined by 19.23% to $18.4 million in 2023, then grew by 19.15% to $21.9 million in 2024, then decreased by 17.64% to $18.1 million in 2025, then decreased by 9.69% to $16.3 million in 2026.
• The last three Share-based Compensation figures came in at $16.3 million (Q1 2026), $18.1 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.